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Chronic myeloid leukemia (CML), which is caused by the BCR–ABL fusion 
tyrosine kinase, is one of the most intensively studied human cancers. ABL 
kinase inhibitors have been spectacularly successful in treating CML, but 
disease persistence and acquired drug resistance can prevent eradication and 
cure of the leukemia. The development of better therapies will depend on a 
full understanding of signaling pathways in CML, facilitated by model studies 
using mutant mice.
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The hematologic neoplasms have been 
the proving ground for targeted can-
cer therapies, in part because the ma-
lignant cells are readily obtained and 
manipulated. One major lesson that 
has emerged is that phenotypically 
similar leukemias may depend on very 
diff  erent signaling pathways for their 
pathogenesis, and thus require very 
diff   erent therapeutic strategies. For 
example, CML and juvenile myelo-
monocytic leukemia (JMML) are both 
characterized by overproduction of ma-
turing myeloid cells, but the signaling 
abnormalities underlying the two dis-
eases are quite diff   erent. The direct 
cause of CML is the product of the 
Philadelphia (Ph) chromosome, the 
BCR–ABL fusion tyrosine kinase (1) 
whose leukemogenic activity depends 
in part on its ability to enhance sur-
vival of myeloid progenitor cells by 
activating antiapoptotic genes. Con-
sistent with a critical role for BCR–
ABL, the ABL kinase inhibitor imatinib 
has been a successful therapy, produc-
ing hematologic and cytogenetic re-
sponses in nearly all CML patients. In 
contrast, JMML cells lack BCR–ABL 
and these patients do not respond 
to imatinib. Instead, JMML cells fre-
quently have activating mutations in 
Ras or SHP2 (a tyrosine phosphatase), or 
loss-of-function mutations in the neuro-
fi  bromatosis-1 protein NF-1 (a negative 
regulator of Ras) (1), which lead to 
enhanced proliferation of JMML my-
eloid progenitors in response to granu-
locyte/macrophage colony-stimulating 
factor (2).
In CML, ABL kinase inhibitor 
therapy induces hematologic and cyto-
genetic remission in most patients, 
but the majority harbor residual dis-
ease detectable by PCR (3), and some 
(particularly those in advanced stages) 
will have progression of leukemia due 
to acquired drug resistance. Both phe-
nomena may refl   ect the relative in-
sensitivity of the leukemia-initiating 
or leukemic “stem” cells to drugs that 
inhibit BCR-ABL kinase activity 
(4, 5). Understanding oncogenic sig-
naling will be of critical importance 
to develop strategies to cure CML and 
other leukemias using targeted thera-
pies. In this commentary, several re-
cent publications that use mutant 
mouse models to illuminate signaling 
pathways critical for the pathogenesis 
of CML and other leukemias will be 
discussed. These include the report 
that mice lacking 12/15-lipoxygenase 
(12/15-LO) develop myeloprolifera-
tive-like disease and down-regulate 
interferon consensus sequence bind-
ing protein, a transcription factor that 
suppresses normal and CML myelo-
poiesis. Other studies help resolve the 
controversy over the role of Stat5 
  activation in promoting CML patho-
genesis, and link Src kinases to 
BCR–ABL+ B lymphoid leukemia 
but not CML.
12/15-LO defi  ciency and 
myeloproliferative disorder (MPD)
In a recent issue of the Journal of 
Experimental Medicine, Middleton et al. 
demonstrated that mice with homo-
zygous null mutations in Alox15, which 
e  ncodes 12/15-lipoxygenase, develop 
MPD (6). 12/15-LO incorporates oxy-
gen into unsaturated lipids to generate 
short-lived peroxides that are ultimately 
converted to 12(S)-hydroxyecosatet-
raenoic acid and related products, which 
have pleiotropic eff  ects on cell signaling 
and the infl  ammatory response. Hema-
topoietic expression of 12/15-LO was 
known to be restricted to myeloid pro-
genitors. No hematologic abnormalities 
have been noted in the mutant mice 
until now, however (even though 
Alox15-null mice have been used for 
many years in atherosclerosis studies), 
possibly because of the decreased pene-
trance of the phenotype in mixed ge-
netic backgrounds.
Middleton et al. reported that al-
though young (6–8-wk old) Alox15–/– 
mice (in a C57BL/6 background) were 
normal, they uniformly developed fea-
tures of an MPD by 10–12 wk of age, 
including increased levels of circulating 
myeloid cells, splenomegaly, and infi  l-
tration of spleen by what appear to be 
proliferating, apoptosis-resistant, imma-
ture myeloid progenitors (6). These ob-
servations in Alox15−/− mice suggest 
that loss or down-regulation of 12/15-
LO could contribute to CML. Indeed, 
the authors went on to show that 
12/15-LO was undetectable in a 
CML cell line and that ectopic expres-
sion of 12/15-LO in these cells mark-
edly decreased their proliferation and 
survival, eff  ects that were partially re-
versed by treatment with an inhibitor 
of 12/15-LO.
An important feature of human 
CML is the progression from the 
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myeloid progenitors to neutrophils is 
close to normal, to blast crisis (BC), a 
terminal phase resembling acute my-
eloid leukemia (AML), where there is 
profound impairment of hematopoietic 
diff  erentiation. Interestingly, a minority 
(?15%) of ageing Alox15–/– mice de-
veloped a condition similar to BC, with 
progressive splenomegaly and increased 
marrow, splenic, and circulating imma-
ture myeloid cells. However, it is not 
clear whether these mice meet defi  ning 
criteria for AML, such as >20% mar-
row myeloblasts (7). The cause of mor-
bidity and death in mice with BC-like 
disease was thought to be severe ane-
mia, based on a relative decrease in ma-
ture erythrocytes in the bone marrow, 
but it is not apparent whether this cor-
related with decreased blood hemoglo-
bin or hematocrit, which are the standard 
criteria for anemia.
The 12/15-LO–interferon consensus 
binding protein connection
How might loss of 12/15-LO lead to a 
CML-like disease? Treatment of spleno-
cytes from these mice in vitro with ima-
tinib did not impair their proliferation 
or survival, nor was there any increase in 
tyrosyl phosphorylation of the ABL sub-
strate Crk, suggesting that dysregulated 
ABL activity is not involved. But the 
authors did establish an intriguing func-
tional connection between 12/15-LO, 
the protein kinase Akt, and interferon 
consensus sequence binding protein 
(ICSBP; also known as IRF-8) (Fig. 1).
Several lines of evidence have pre-
viously implicated ICSBP, an interferon-
stimulated transcriptional repres  sor, 
as a suppressor of normal and CML 
  myelopoiesis. ICSBP transcripts are low 
to absent in chronic phase CML (8), 
and ISCBP-defi  cient mice develop an 
MPD-like syndrome (9), in which the 
myeloid progenitors are hypersensitive 
to myeloid growth factors including 
granulocyte/macrophage colony-stimu-
lating factor and interleukin-3 (10). In 
mouse bone marrow, ICSBP activation 
is decreased by BCR–ABL, whereas en-
forced coexpression of ICSBP attenu-
ates both normal and BCR–ABL+ 
Figure 1.  Schematic representation of signaling in myeloid pro-
genitors. (A) Interferon-α (IFN-α) induces ICSBP transcription through 
Stat1. Increased ICSBP mediates an antileukemic effect through an un-
known mechanism. (B) The BCR–ABL kinase represses ICSBP transcription 
through an unknown mechanism, but also activates multiple signaling 
pathways, including Ras-MAPK (leading to induction of Bcl-2 gene tran-
scription), Stat5 (leading to Bcl-X gene transcription), PI3K (through 
a Grb2–Gab2 interaction) leading to Akt activation, and Src family 
kinases (Lyn and Hck). The net effect of BCR–ABL activity is to promote 
Bcl-2 and Bcl-X expression and to inhibit ICSBP transcription. (C) In con-
trast, 12/15-LO may either activate PTEN or inhibit PDK1, both regula-
tors of Akt, leading to increased phosphorylation and cytoplasmic 
localization of ICSBP, an effect mediated in part through an unknown 
tyrosine kinase. This may increase survival in myeloid progenitors through 
relief of ISCBP-mediated inhibition of Bcl-2 and Bcl-X. PIP3, phosphatidyl 
inositol-3,4,5-triphosphate.COMMENTARY
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granulopoiesis (11). Direct repression 
targets of ICSBP in myeloid cells, which 
may account for this activity, include 
the antiapototic genes Bcl-X (12) and 
Bcl-2 (13).
Middleton et al. found that nuclear 
ICSBP protein levels were reduced in 
splenocytes from Alox15–/– mice with 
MPD (6). This decrease in nuclear IC-
SBP correlated with increased a ctivation 
of Akt, enhanced tyrosyl phosphoryla-
tion of ICSBP, and elevated expression 
of Bcl-2. Prevention of Akt activation 
by treatment with a phosphatidylinosi-
tol 3-kinase (PI3K) inhibitor reduced 
ICSBP tyrosyl phosphorylation and in-
creased nuclear ICSBP levels, coinci-
dent with reduced Bcl-2 levels and 
increased apoptosis. The mechanism 
through which 12/15-LO defi  ciency 
activates PI3K was not defi  ned, but it is 
possible that some 12/15-LO products 
aff  ect PI3K regulators such as PTEN or 
PDK1 (Fig. 1). The fi  ndings  further 
suggest that a tyrosine kinase is involved 
in regulating ICSBP, but aside from ex-
cluding ABL, the authors did not pur-
sue the identity of this kinase.
Nice model, but is it CML?
Alox15–/–-defi   cient mice clearly have 
overproduction of maturing myeloid 
cells and splenomegaly. But is this 
model relevant to CML? One problem 
in diagnosing MPD is that the malig-
nant cells are virtually identical to nor-
mal maturing myeloerythroid cells, so 
that distinguishing MPD from reactive 
conditions is diffi   cult (1). An undiag-
nosed generalized infl  ammatory state in 
older Alox15–/– mice could explain the 
myeloproliferation, but 12/15-LO and 
its products are generally considered to 
be proinfl   ammatory, arguing against 
this possibility. Two cardinal features 
that distinguish leukemia from reactive 
conditions are clonality and transplant-
ability. Because Alox15–/– mice are ini-
tially normal, 12/15-LO defi  ciency 
alone may be insuffi   cient for develop-
ment of MPD; additional events might 
be required for progression to MPD 
and subsequently to the blastic phase. In 
the Middleton et al. paper, the authors 
could not determine whether the MPD 
or blast phase are clonal processes (6), 
but future retroviral marking studies may 
resolve this. They were unable to adop-
tively transfer disease from Alox15–/– 
MPD mice by transplantation of bone 
marrow and/or splenocytes to synge-
neic, unirradiated recipients, which 
probably refl  ects the very poor engraft-
ment of donor hematopoietic stem cells 
under these conditions (14). However, 
they were able to effi   ciently transfer he-
matopoietic disease (defi  ned as modest 
splenic enlargement with disruption of 
architecture) when donors in the “blast” 
phase were used, although the extent of 
donor engraftment and whether recipi-
ents developed fatal AML were not 
documented. These results suggest that 
the  Alox15–/– donor cells capable of 
transferring disease (i.e., the leukemia-
initiating or leukemic “stem” cells) dif-
fer between the MPD and blast phases 
of the disease, which is reminiscent of 
human CML (15). It would also be 
  informative to test whether Alox15–/– 
myeloid progenitors were hypersensi-
tive to cytokines, as in ICSBP defi  ciency 
(10). Cytokine hypersensitivity would 
connect decreased ICSBP function di-
rectly with the enhanced myelopoiesis 
in  Alox15–/– mice, but it would also 
suggest that the disease is more like 
JMML (2) than CML, where the cyto-
kine response is normal (16).
Ultimately, whether Alox15–/– mice 
represent an informative model of CML 
will require further study. There are 
some tantalizing clinical correlates, in-
cluding decreased 12-LO activity in 
CML marrow cells (17) and frequent 
loss at chromosome 17p, where 
ALOX15 is located, in CML disease 
progression. However, some functional 
connection between BCR–ABL and 
12/15-LO (for example, does BCR–
ABL alter 12/15-LO activity or expres-
sion?) is needed to support the proposed 
role of 12/15 LO in CML (Fig. 1). 
  Although both BCR–ABL activity and 
12/15-LO defi   ciency activate Akt in 
myeloid progenitors, the eff  ects  on 
ICSBP in the two myeloproliferative 
syndromes are distinct, with BCR–
ABL decreasing ICSBP transcripts and 
  protein expression, whereas 12/15-LO 
defi  ciency impairs nuclear localization 
of ICSBP but not its overall expression. 
Abnormalities of the 12/15-LO path-
way should be sought in Ph-negative 
(atypical) CML and in chronic neutro-
philic leukemia, two CML-like MPDs 
that lack BCR–ABL (1), and in my-
eloid blast crisis of CML. Whether or 
not the analogy to CML holds up, the 
Alox15–/– mice are certain to provide 
important new insights into normal and 
malignant myelopoiesis.
Stat5 and CML: superfl  uous 
or signifi  cant?
ICSBP intersects with another well-
studied hematopoietic signaling system 
that has been implicated in CML onco-
genesis, the JAK-Stat pathway. Activa-
tion of the latent transcription factor, 
signal transducer and activation of tran-
scription 5 (Stat5), in BCR–ABL-ex-
pressing cell lines and primary leukemia 
cells was recognized a decade ago (18), 
but the role of Stat5 in the pathogenesis 
of CML has been controversial. BCR–
ABL may activate Stat5 through direct 
phosphorylation, or the activation could 
be indirect, via phosphorylation by 
JAK2 (19) or by Src family kinases (20), 
both of which are activated in BCR–
ABL-expressing cells (Fig. 1). In a 
mouse retroviral bone marrow trans-
duction/transplantation model of CML, 
initial studies using donor mice with 
targeted mutations in Stat5a and Stat5b 
suggested that Stat5 was not absolutely 
required for induction of CML-like 
leukemia by BCR–ABL (21). How-
ever, it is now widely recognized that 
the  Stat5a/b mutations used in these 
studies were hypomorphic rather than 
true null alleles (22).
The role of Stat5 in CML has been 
readdressed in two recent papers. In 
the fi   rst paper, induction of murine 
CML-like MPD was attenuated in 
  donor hematopoietic cells with a single 
null mutation in Stat5a (23), indicating 
that this Stat5 isoform has a nonredun-
dant function in BCR–ABL leukemo-
genesis. The second paper used novel 
mice that have the entire Stat5ab locus 
deleted (24). Stat5ab–/– mice die peri-
natally, but fetal liver hematopoietic 
  pro  genitors from these mice were inca-
pable of generating leukemia in recipi-
ent mice after retroviral transduction 464  NEW INSIGHTS INTO CML SIGNALING | Van Etten
with BCR–ABL (25). Together with a 
recent report that siRNA against Stat5 
in human CML patient samples impairs 
Ph+ myeloid colony formation (26), 
these studies suggest that Stat5 signaling 
contributes to BCR–ABL leukemo-
genesis. However, several important 
  issues must be clarifi  ed. The Stat5ab–/– 
experiments addressed principally B 
lymphoid transformation and leukemo-
genesis rather than CML-like MPD, 
and the extent that nonmalignant 
Stat5ab–/– hematopoietic stem cells can 
contribute to stable myeloerythropoie-
sis after transplantation has not been 
defi  ned. Lastly, the important transcrip-
tional targets of Stat5 in CML must be 
determined. In this regard, there is con-
siderable evidence that Bcl-X, a target 
for repression by ICSBP (12), is tran-
scriptionally activated by Stat5 in CML 
cells (27) and may contribute to in-
creased survival (Fig. 1).
Src kinases in BCR–ABL leukemogenesis: 
a lineage-specifi  c role
As mentioned in the previous section, 
BCR–ABL activates multiple Src family 
kinases through a mechanism that does 
not involve direct phosphorylation, and 
Src kinase inhibitors and dominant-
  negative mutants impair BCR–ABL 
transformation in cultured cells (28). 
However, BCR–ABL can effi   ciently 
induce CML-like MPD in marrow 
from mice lacking the three Src kinases 
principally expressed in myeloid pro-
genitor and stem cells (Lyn, Hck, and 
Fgr), suggesting that these Src kinases 
have no role in the pathogenesis of 
chronic phase CML (29). In contrast, 
induction of B cell acute lymphoblastic 
leukemia (B-ALL), which is also BCR–
ABL dependent, was dramatically im-
paired in the absence of any two of these 
three Src kinases, suggesting a partially 
redundant requirement for Src kinases 
in the pathogenesis of Ph+ B-ALL and 
the B lymphoid BC stage of CML (29). 
Subsequently, these fi  ndings were sup-
ported by the demonstration that siRNA 
knockdown of Lyn in primary CML 
cells impaired leukemic cell viability and 
colony formation in cells from patients 
with Ph+ lymphoid BC, but had less 
  eff  ect on myeloid BC cells (30).
Several pharmaceutical companies 
have developed drugs that inhibit the ki-
nase activity of both BCR–ABL and Src 
kinases, some of which are active against 
many but not all of the BCR–ABL ima-
tinib-resistant mutants (31, 32). The 
studies with Lyn/Hck/Fgr-defi  cient 
mice showed that those particular Src ki-
nases were not required for induction of 
CML-like disease by BCR–ABL (29), 
but involvement of the other six Src 
family members could not be excluded. 
When administered to mice with BCR–
ABL-induced CML-like MPD or B-ALL, 
the ABL kinase inhibitor imatinib 
(Gleevec) prolonged the survival of mice 
with either disease, whereas CGP76030, 
a small molecule inhibitor of Src kinases 
that also inhibits BCR–ABL at higher 
concentrations (28), was eff  ective alone 
and synergized with imatinib in mice 
with B-ALL, but had no eff  ect in mice 
with CML-like leukemia (29). Bio-
chemical analysis of primary leukemia 
cells showed that, at the doses used, 
CGP76030 inhibited Src family kinases 
but not BCR–ABL. A novel genetic 
strategy has been developed to verify the 
in vivo therapeutic target of dual ABL/
Src kinase inhibitors in the Ph+ leuke-
mias. The BCR–ABL T315I mutant is 
resistant to both imatinib (33) and the 
dual ABL/Src inhibitor dasatinib (BMS-
354825) (31). B lymphoid blasts trans-
formed by BCR–ABL T315I are 
relatively resistant to imatinib but sus-
ceptible to dasatinib in vitro and in vivo 
(5), implying that inhibition of BCR–
ABL alone is insuffi   cient for therapeutic 
responses in Ph+ B-ALL. The results fur-
ther suggest that pure Src kinase inhibi-
tors will have little therapeutic activity in 
chronic phase CML patients, but could 
be useful in the treatment of Ph+ B-ALL 
and CML lymphoid blast crisis. This pre-
diction has been born out clinically, as 
patients with chronic and accelerated 
phase CML and the T315I mutation do 
not respond to dasatinib (34).
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